103 related articles for article (PubMed ID: 1370199)
1. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.
Clayman GL; Liu FJ; Savage HE; Taylor DL; Lavedan P; Buchsbaum RM; Pellegrino C; Trujillo JM; Young G; Schantz SP
Arch Otolaryngol Head Neck Surg; 1992 Jan; 118(1):41-8. PubMed ID: 1370199
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins.
Clayman GL; Liu FJ; Taylor DL; Savage HE; Lavedan P; Buchsbaum RM; Trujillo JM; Schantz SP
Otolaryngol Head Neck Surg; 1991 Jul; 105(1):26-34. PubMed ID: 1715542
[TBL] [Abstract][Full Text] [Related]
3. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
[TBL] [Abstract][Full Text] [Related]
4. Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with interleukin-2 and interferon alpha.
Clayman GL; Young G; Taylor DL; Savage HE; Lavedan P; Schantz SP
Ann Otol Rhinol Laryngol; 1992 Nov; 101(11):909-15. PubMed ID: 1444098
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
6. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
Bugis SP; Lotzová E; Savage HE; Hester JP; Racz T; Sacks PG; Schantz SP
Cancer Immunol Immunother; 1990; 31(3):176-81. PubMed ID: 2337906
[TBL] [Abstract][Full Text] [Related]
8. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
10. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of interleukin-2 and interferon-alpha in head and neck cancer.
Schantz SP; Dimery I; Lippman SM; Clayman GL; Pellegrino C; Morice R
Invest New Drugs; 1992 Aug; 10(3):217-23. PubMed ID: 1428731
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.
Bailet JW; Lichtenstein A; Chen G; Mickel RA
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):855-62. PubMed ID: 9260552
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 and acute-phase proteins in head and neck cancer.
Gallo O; Gori AM; Attanasio M; Martini F; Giusti B; Brunelli T; Gallina E
Eur Arch Otorhinolaryngol; 1995; 252(3):159-62. PubMed ID: 7544987
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma.
Pardo L; Valero C; López M; García J; Camacho M; Quer M; León X
Auris Nasus Larynx; 2017 Jun; 44(3):313-318. PubMed ID: 27401121
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
17. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
[TBL] [Abstract][Full Text] [Related]
18. The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer.
Schantz SP; Clayman G; Racz T; Grimm EA; Liu FJ; Lavedan P; Taylor D; Pellegrino C; Savage H
Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1302-8. PubMed ID: 2242261
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma of the head and neck.
Duvall AJ; Adams GL; Pollak K; Charyulu K
Minn Med; 1973 Jun; 56(6):480-91. PubMed ID: 4710970
[No Abstract] [Full Text] [Related]
20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
